While effectively operating the existing business, adequately leveraging on our shareholders' capital strengths and management team's entrepreneurial potential, we aim to enlarge and strengthen the Company through investment, acquisition, merger, re-alignment and cooperation and rapidly develop into a sizeable pharmaceutical group within the industry:

Possess excellent growth potential and ability to grow at a steadily healthy pace;

Profitability that will lead to reasonable investment returns;

Long-term development strategies, high-end product reserve and trustworthy strategic business partners;

Corporate structure arrangements that provide a foundation for expansion and room for development;

A superior and reliable management team together with a committed workforce to lead the Company’s sustainable development.

The Company is committed to the strategic focuses of “Solidity, Specialization, Strength, Size, and Breadth”.

Solidity---solidify asset base and management foundation

Specialization---specialize in the area of Rheumatoid Arthritis (RA)

Strength---profit maximization with matching cashflow

Size---ensure steady expansion of sales

Breadth---enrich existing RA product range and develop the Paeonia business line

On the basis of solidity we specialize; in the process of specialization we strengthen; on a strong foundation we increase in size and from a large, strong basis we grow in breadth. We thrive to become the industry leader and the single champion in China's RA specialization.